SUMO1 and glioblastoma: Therefore, both the isomerase activity of Pin1 and the kinase activity of CDK1 may be key targets for inhibition of SUMO1-modified protein sumoylation, and simultaneous inhibition of Pin1 and CDK1 should strongly benefit GBM treatment.